NCT03932513

Evaluating the Effects of Inarigivir on Immune Response and Viral Markers in Chronic Hepatitis B Patients

A Phase 2, Open-label Study Evaluating the Intra-hepatic Effect of Inarigivir 400 mg Per Day and 400 mg Three Times Per Week on Immune Response and Viral Markers in Virally Suppressed Patients With Chronic Hepatitis B Infection

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: F-star Therapeutics, Inc. · Industry
• Sex: All
• Age: 21 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

A single center, open-label, study to evaluate the intra-hepatic effect of inarigivir dose per day and three times per week on immune response and viral markers in virally suppressed patients with chronic hepatitis B infection

Detailed description

This is a single center, open-label, study to evaluate the intra-hepatic effect of inarigivir dose per day and three times per week on immune response and viral markers in virally suppressed patients with chronic hepatitis B infection

Conditions

• HBV
• Hepatitis B
• Hepatitis B, Chronic

Interventions

Type	Name	Description
DRUG	inarigivir soproxil	Inarigivir 200mg and 400mg oral tablets, once daily

Timeline

• Start date: 2019-04-11
• Primary completion: 2019-12-21
• Completion: 2019-12-21
• First posted: 2019-04-30
• Last updated: 2020-04-29

Locations

1 site across 1 country: Singapore